- Home
- DSM vs AQST Comparison
DSM vs AQST Comparison
Compare DSM & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- AQST
- Stock Information
- Founded
- DSM 1989
- AQST 2004
- Country
- DSM United States
- AQST United States
- Employees
- DSM N/A
- AQST N/A
- Industry
- DSM Investment Managers
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- AQST Health Care
- Exchange
- DSM Nasdaq
- AQST Nasdaq
- Market Cap
- DSM 289.7M
- AQST 274.4M
- IPO Year
- DSM N/A
- AQST 2018
- Fundamental
- Price
- DSM $5.81
- AQST $2.88
- Analyst Decision
- DSM
- AQST Strong Buy
- Analyst Count
- DSM 0
- AQST 7
- Target Price
- DSM N/A
- AQST $10.57
- AVG Volume (30 Days)
- DSM 161.7K
- AQST 1.5M
- Earning Date
- DSM 01-01-0001
- AQST 03-05-2025
- Dividend Yield
- DSM 3.97%
- AQST N/A
- EPS Growth
- DSM N/A
- AQST N/A
- EPS
- DSM N/A
- AQST N/A
- Revenue
- DSM N/A
- AQST $57,561,000.00
- Revenue This Year
- DSM N/A
- AQST N/A
- Revenue Next Year
- DSM N/A
- AQST $35.72
- P/E Ratio
- DSM N/A
- AQST N/A
- Revenue Growth
- DSM N/A
- AQST 13.80
- 52 Week Low
- DSM $4.69
- AQST $2.24
- 52 Week High
- DSM $6.05
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- DSM 36.50
- AQST 47.99
- Support Level
- DSM $6.01
- AQST $2.45
- Resistance Level
- DSM $6.10
- AQST $3.06
- Average True Range (ATR)
- DSM 0.05
- AQST 0.20
- MACD
- DSM -0.02
- AQST 0.03
- Stochastic Oscillator
- DSM 9.27
- AQST 60.66
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.